T细胞炎症表型与杜韦利西布治疗慢性淋巴细胞白血病自身免疫毒性相关
研究探讨杜韦利西布联合FCR方案治疗初治慢性淋巴细胞白血病时自身免疫毒性的T细胞机制。约三分之一患者出现自身免疫毒性,毒性患者中活化CD8 T细胞、颗粒酶阳性Treg及Th17 CD4和CD8 T细胞增加,Th17相关细胞因子IL-17A和IL-21相对升高。结论认为活化CD8 T细胞增加伴Th17激活,在基线Treg较低和CLL对杜韦利西布抵抗较强背景下,与杜韦利西布相关自身免疫毒性相关。
要点
- 杜韦利西布联合FCR治疗初治CLL时约三分之一患者发生自身免疫毒性。
- 毒性患者中活化CD8 T细胞、颗粒酶阳性Treg及Th17 CD4和CD8 T细胞增加。
- Th17相关细胞因子IL-17A和IL-21在毒性患者中相对升高。
核心结论
- 活化CD8 T细胞增加伴Th17 T细胞激活,在基线Treg较低和CLL对杜韦利西布抵抗较强背景下,与杜韦利西布相关自身免疫毒性相关。
研究设计与样本
- 研究分析杜韦利西布联合FCR化学免疫治疗初治慢性淋巴细胞白血病患者的T细胞亚群和细胞因子。
- 原文未报告样本量。
主要发现
- 杜韦利西布联合FCR治疗调节CD4和CD8 T细胞亚群及促炎细胞因子。
- 治疗中初始和中央记忆CD4 T细胞及初始CD8 T细胞减少,活化CD8 T细胞、颗粒酶阳性Treg及Th17 CD4和CD8 T细胞增加,毒性患者中尤为明显。
- Th17激活相关细胞因子IL-17A和IL-21在毒性患者中相对升高。
- 唯一与毒性相关的CLL特征是基线凋亡启动增加,杜韦利西布治疗第一周内显著下降。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several PI3Kδ inhibitors are approved for the therapy of B cell malignancies, but their clinical use has been limited by unpredictable autoimmune toxicity. We have recently reported promising efficacy results in treating chronic lymphocytic leukemia (CLL) patients with combination therapy with the PI3Kδγ inhibitor duvelisib and fludarabine cyclophosphamide rituximab (FCR) chemoimmunotherapy, but approximately one-third of patients develop autoimmune toxicity. We show here that duvelisib FCR treatment in an upfront setting modulates both CD4 and CD8 T cell subsets as well as pro-inflammatory cytokines. Decreases in naive and central memory CD4 T cells and naive CD8 T cells occur with treatment, while activated CD8 T cells, granzyme positive Tregs, and Th17 CD4 and CD8 T cells all increase with treatment, particularly in patients with toxicity. Cytokines associated with Th17 activation (IL-17A and IL-21) are also relatively elevated in patients with toxicity. The only CLL feature associated with toxicity was increased priming for apoptosis at baseline, with a significant decrease during the first week of duvelisib. We conclude that an increase in activated CD8 T cells with activation of Th17 T cells, in the context of lower baseline Tregs and greater CLL resistance to duvelisib, is associated with duvelisib-related autoimmune toxicity.
引用
- Gadi D, Griffith A, Tyekucheva S, et al. A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemia. Leukemia. 2021. PMID: 34743191. doi:10.1038/s41375-021-01441-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。